A single dose of an experimental jab has been found to cut “bad” cholesterol levels by half within six months of treatment in a small Chinese gene-editing trial, a new study reveals.
The therapy is being developed for the treatment of familial hypercholesterolemia, a life-threatening hereditary disease that causes abnormally high levels of fats in the blood.
